Roth Capital Still Sees 51% Upside For Sarepta’s Stock
In a research report issued yesterday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT) with a $34 price target, which represents a potential upside of 51% from where the stock is currently trading.
Chattopadhyay said, “SRPT’s investigational influenza compound (AVI-7100) has moved to multiple ascending dose testing in healthy volunteers. Importantly, AVI-7100 is based on SRPT’s advanced PMOplus platform, which could lead to lower dose and better COGS compared to the parent PMO chemistry. However, our short-term focus is on the initiation of patient dosing in the DMD pivotal study , hopefully prior to 3Q14 corporate update in November.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -2.1% and a 22.2% success rate. Chattopadhyay has a -12.0% average return when recommending SRPT, and is ranked #2832 out of 3313 analysts.